brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastische mittel - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
ipravent 20 mikrogramm/sprühstoß druckgasinhalation, lösung
cipla europe nv (8154263) - ipratropiumbromid 1 h<2>o - druckgasinhalation, lösung - teil 1 - druckgasinhalation, lösung; ipratropiumbromid 1 h<2>o (19720) 20,87 mikrogramm
quetiapin intas 200 mg retardtabletten
intas pharmaceuticals ltd - quetiapin fumarat -
quetiapin intas 300 mg retardtabletten
intas pharmaceuticals ltd - quetiapin fumarat -
quetiapin intas 400 mg retardtabletten
intas pharmaceuticals ltd - quetiapin fumarat -
quetiapin intas 50 mg retardtabletten
intas pharmaceuticals ltd - quetiapin fumarat -
quetiapine intas pharmaceuticals 50 mg retardtablette
intas pharmaceuticals - quetiapine fumarate - retardtablette - 50 mg - quetiapine fumarate 57.575 mg - quetiapine
quetiapine intas pharmaceuticals 200 mg retardtablette
intas pharmaceuticals - quetiapine fumarate - retardtablette - 200 mg - quetiapine fumarate 230.3 mg - quetiapine